2 weeks Ago By ABMN Staff
Pharming Group ( NASDAQ:PHAR – Get Free Report ) gapped up prior to trading on Friday . The stock had previously closed at $8.03, but opened at $8.
32. Pharming Group shares last traded at $8.39, with a volume of 2,832 shares changing hands.
Analysts Set New Price Targets Separately, HC Wainwright reissued a “buy” rating and issued a $37.00 target price on shares of Pharming Group in a research report on Thursday. Read Our Latest Stock Report on PHAR Pharming Group Trading Up 5.
7 % Pharming Group ( NASDAQ:PHAR – Get Free Report ) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.01) earnings per share (EPS) for the quarter.
Pharming Group had a negative return on equity of 5.69% and a negative net margin of 4.65%.
The firm had revenue of $74.09 million for the quarter, compared to analyst estimates of $71.95 million.
During the same quarter in the prior year, the business posted $0.02 EPS. On average, analysts expect that Pharming Group will post -0.
15 EPS for the current fiscal year. Institutional Inflows and Outflows A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its holdings in shares of Pharming Group ( NASDAQ:PHAR – Free Report ) by 32.
3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,435 shares of the company’s stock after acquiring an additional 5,725 shares during the quarter. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 at the end of the most recent quarter.
Institutional investors and hedge funds own 0.03% of the company’s stock. About Pharming Group ( Get Free Report ) Pharming Group N.
V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Further Reading Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter ..
